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Abstract  
Mebendazole (MBZ) was identified as a promising therapeutic based upon its ability to induce 
apoptosis in melanoma cell lines via a BCL2 dependent mechanism. We now show that in a 
human xenograft melanoma model, oral MBZ is as effective as the current standard of care 
temozolomide (TMZ) in reducing tumor growth. Inhibition of melanoma growth in vivo is 
accompanied by phosphorylation of BCL2 and decreased levels of XIAP. Reduced expression of 
XIAP upon treatment with MBZ is partially mediated by its proteasomal degradation. Furthermore, 
exposure of melanoma cells to MBZ promotes the interaction of SMAC/DIABLO with XIAP, 
thereby alleviating XIAP’s inhibition on apoptosis. XIAP expression upon exposure to MBZ is 
indicative of sensitivity to MBZ as MBZ resistant cells do not display reduced levels of XIAP after 
treatment. Resistance to MBZ can be partially reversed by siRNA knockdown of cellular levels of 
XIAP. Our data suggest that MBZ is a promising anti-melanoma agent based upon its effects on 
key antiapoptotic proteins. 
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Introduction 
Melanoma is the most aggressive form of skin cancer, with a high propensity to metastasize. 
Based on National Cancer Institute estimates, the lifetime risk of a person in the USA developing 
melanoma has doubled in the last 20 years [1]. Because the risk of developing melanoma may be 
correlated with UV exposure and recent societal trends have resulted in increased sun exposure, 
the increasing trend is expected to continue its trajectory [2]. Despite recent advances in the 
treatment of melanoma using targeted therapies, patients still face a dismal prognosis as most 
responses are transient, with relapse and resistance occurring in most cases [3]. Temozolomide, 
the standard of care for advanced non-mutant BRAF melanoma and often administered in 
vemurafenib-resistant melanoma, is associated with response rates of less than 20% [4].   
 
Drug repositioning is the application of known drugs to new indications. Given the successes for a 
number of repositioned drugs including duloxetine, sildenafil, and thalidomide, the process has 
become recognized as an effective alternative to the development of novel chemical entities [5,6]. 
Because repositioned drugs have often been through several stages of clinical development, and 
in many cases are already marketed, the time and cost required to take a drug from bench to 
bedside is dramatically reduced.  With regard to the immediate clinical need for effective 
melanoma therapies, drug repositioning holds the promise of a rapid solution to a pressing clinical 
problem. Here, we present data demonstrating that mebendazole (MBZ), currently marketed in 
the US as an oral anti-parasitic drug with a remarkable safety profile, also exhibits promising anti-
melanoma growth properties in vivo.  
 
Mebendazole has been used extensively to safely treat gastrointestinal parasitic infections in 
humans for over 50 years [7,8]. In the treatment of common roundworms, hookworms, and 
whipworms, adults and children 2 years of age and older are administered 100 mg two times a 
day, morning and evening, for three days. In addition, mebendazole has also demonstrated 
effectiveness in the management of cystic echinococcosis (also called “hydatid cysts”) and 
alveolar echinococcosis. For treatment of these conditions, mebendazole is administered at 
higher doses for prolonged periods of time. Mebendazole is typically used at a dosage of 40-50 
mg/kg body weight either continuously or administered as 1–6 monthly cycles separated by 10–
14 day intervals. [9]. Multiple studies have demonstrated that mebendazole is generally well 
tolerated for extended periods of time at this dose with rare reported adverse reactions including 
hepatotoxicity and gastrointestinal disturbances [10,11,12].  
 
Melanoma’s noted intrinsic resistance to therapy has been attributed to modulation of cellular 
survival pathways including apoptosis. We originally reported that MBZ, which acts as a 
microtubule-disrupting agent, is a potent inducer of phosphorylation of BCL2 and apoptosis in 
melanoma cells in vitro. Here, we show that in addition to its effects on BCL2, MBZ also 
modulates another key anti-apoptotic factor, X-linked inhibitor of apoptosis (XIAP), to promote 
melanoma apoptosis both in vitro and in vivo. XIAP is an important regulator of cellular apoptosis 
through direct binding to caspases and inhibition of their proteolytic activity [13]. Given its 
function, it is surmised that XIAP may play a critical role in melanoma chemoresistance. Indeed, 
overexpression of XIAP imparts resistance to various chemotherapies in vitro [14]. XIAP 
expression has also been shown to increase with progressive disease stage in melanoma [15].  
 
Here we demonstrate that MBZ inhibits human melanoma xenograft growth and is accompanied 
by reduced XIAP expression. In vitro, MBZ mediated induction of apoptosis in melanoma cells 
involves enhanced interaction between XIAP and SMAC/DIABLO and subsequent proteasomal 
degradation of XIAP. This cellular response does not occur in cells resistant to MBZ and may 
serve as a potential biomarker of treatment response.  
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Methods  
Reagents and cell lines: Human melanoma cell lines were cultured in DMEM supplemented 
with 10% FCS, 5 units/mL penicillin, and 5 μg/mL streptomycin. SK-Mel-19 was kindly provided 
by Alan Houghton (Memorial Sloan-Kettering Cancer Center, New York, NY). M-14 cells were a 
generous gift from Gabriella Zupi (Instituto Regina Elena, Rome, Italy). A-375 was obtained from 
American Type Culture Collection (St. Louis, MO). The following cell lines were provided by Dr 
Pamela Pollock: MM622, MM540, D08, MM329, D17, and UACC1097 (UACC1097 was supplied 
by the Arizona Cancer Center Cell Culture Shared Resource, Tucson, AZ). All cells were 
maintained in an incubator with a humidified atmosphere of 5% CO2 at 37C. TMZ (NSC 362856) 
was kindly provided by the National Cancer Institute (Bethesda, MD). Mebendazole and MG132 
were purchased from Sigma Aldrich (St. Louis, MO). 
 
Xenograft studies: All animals were handled in strict accordance with good animal practice as 
defined by the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory 
Animals, and the Public Health Service (PHS) Policy on Humane Care and Use of Laboratory 
Animals. Animal protocols were approved by the Institutional Animal Care and Use Committee at 
New York University School of Medicine. Athymic female nude mice aged 4-6 weeks (Taconic, 
Germantown, NY)  were injected subcutaneously into the left flank  with 2 × 10
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 M-14 melanoma 
cells with 50% Matrigel (BD Biosciences, San Jose, CA) for tumor implantation. Mice were 
maintained in ventilated cages and fed/watered ad libertum with experiments carried out under an 
IACUC approved protocol as well as following institutional guidelines for the proper and humane 
use of animals in research. After development of a 3-5mm tumor (within 14 days), mice were 
randomly divided into one of four experimental groups: 1 mg MBZ administered by gavage every 
other day, 2 mg MBZ administered by gavage every other day, 100 mg/kg TMZ administered by 
intraperitoneal injection for 5 days, and DMSO administered by intraperitoneal injection for 5 days 
(mock-treated controls). Each experimental group consisted of 10 mice; the experiment was 
repeated three times. Treatment was administered for 5 weeks. During this time, mice were 
monitored for tumor growth through twice weekly caliper measurements of tumor diameter 
(determined by cross-sectional diameter) and tumor volume (using the formula a
2
b/2, in which a 
is the short diameter of the tumor and b is the long diameter of the tumor). After the full course of 
treatment, mice were sacrificed by CO2 euthanasia. Tumors were extracted and immediately 
frozen at −80°C. 
 
Protein extraction and Western blotting: Cells and/or homogenized tumors were harvested in 
extraction buffer containing 1% Triton X-100, 50 mmol/L Tris, 2 mmol/L EDTA, 150 mmol/L NaCl 
(pH 7.5), protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN) and phosphatase 
inhibitor cocktail (Sigma Aldrich, St Louis, MO). The lysates were centrifuged at 10,000 × g, 4°C 
for 10 min in a microcentrifuge with protein concentration of supernatant determined with a 
protein assay kit (Bio-Rad, Hercules, CA). Proteins were separated by 10% SDS-PAGE and 
transferred onto polyvinylidenedifluoride membranes (Polyscreen, Perkin-Elmer, Waltham, MA). 
Estimation of protein molecular weight was determined through use of Precision Plus 
Kaleidoscope Protein Standard (BioRad, Hercules, CA). Antibodies against cleaved poly(ADP-
ribose) polymerase (PARP, Cat. No. 9541), cleaved caspase 9 (Cat No. 9501), cleaved caspase 
3 (Cat No. 9661) and XIAP (Cat No. 2042) were obtained from Cell Signaling Technology 
(Danvers, MA). BCL2 (Cat. No. sc-7382) and SMAC/DIABLO (Cat. No. sc-22766) antibodies 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Phosphorylated forms of BCL2 
protein appear as more slowly migrating species [16,17]. Anti-actin (Cat. No. A2103; Sigma 
Aldrich, St. Louis, MO) was used as a control. Immunoreactive bands were visualized using 
enhanced chemiluminescence detection reagent (Perkin-Elmer, Waltham, MA) and X-OMAT 
processing. 
 
Immunoprecipitation: Cells were treated with MBZ for indicated times and then lysed in NP40 
buffer [50 mmol/L Tris-HCl, 150 mmol/L NaCl, 1% NP40 (pH 8.0)] containing protease inhibitor 
cocktail and phosphatase inhibitor cocktail. Protein (150 μg) was combined with 10 μL anti-
SMAC/DIABLO (Cat. No. sc-22766; Santa Cruz Biotechnology, Santa Cruz, CA) or anti-XIAP 
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(Cat No. 9661; Cell Signaling Technology, Danvers, MA) antibodies and incubated at 4°C 
overnight. Immobilized protein A/G slurry (100 μL; Thermo Fischer Scientific, Rockford, IL) was 
added to the antigen-antibody complex and incubated at room temperature for 2 h with gentle 
mixing. After several washes with water, loading buffer was added to the slurry. The solution was 
incubated for 5 min at 95°C. From each sample, 30 μL of solution was used for evaluation by 
SDS-PAGE gel as described above.  
 
MTS(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H 
tetrazolium) assay: Following treatment with MBZ, cellular proliferation was assessed using a 
tetrazolium dye reduction assay (CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay, 
Promega, Madison, WI) performed according to the manufacturer's instructions as previously 
described. Absorbance was recorded on a microplate reader at 495 nm. In Figure 5, cellular 
proliferation was expressed as percentage with vehicle-treated cells set at 100%.  
 
Sulphorhodamine (SRB) assay: The growth inhibitory effect of MBZ was also measured using 
the SRB assay (Sigma Aldrich, St Louis, MO). Cells were plated in 96 well plates. The following 
day MBZ was added at half-log serial dilutions (10 µM to 1 nM).  The SRB assay was performed 
72 hours following drug. Data was analyzed and GI50 values were generated by nonlinear 
regression analysis with variable slope using Prism software (GraphPad Software, La Jolla, CA). 
 
Statistics: Unless otherwise noted, experiments were performed in triplicate. All data are 
presented as the average ± standard error of the mean [18]. P values were determined by a two-
sided Student's t test with unequal variance, with P< 0.05 considered significant. 
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Results and Discussion 
 
Mebendazole effectively inhibits melanoma xenograft growth 
We originally identified MBZ as a potent inducer of Bcl2 phosphorylation and apoptosis in 
melanoma cell lines [17]. Based upon its promising in vitro activity, we wanted to assess the 
ability of MBZ to suppress melanoma tumor growth in vivo using a human melanoma xenograft 
model established from M-14 cells. We tested four experimental groups in these studies: 1 mg 
MBZ by gavage every other day, 2 mg MBZ by gavage every other day, 100 mg/kg TMZ by 
intraperitoneal (i.p.) injection for 5 days, and DMSO by intraperitoneal injection for 5 days 
(controls). MBZ concentrations are based upon upper and lower dosing equivalents used in long 
term treatment regimes for hydatid parasitic cysts [19]. TMZ treatment was used as a positive 
control, as it is a current standard of care for melanoma. The high dose of TMZ (100 mg/kg 
administered daily for 5 days) was chosen as it is commonly used for preclinical melanoma 
studies [20,21,22]. The results showed that MBZ inhibited M-14 melanoma xenograft tumor 
growth comparably at both doses tested (tumor growth inhibition = 83%, 77%, for 1 mg and 2 mg 
dosing, respectively). These data suggest that oral MBZ inhibits tumor growth as effectively as 
high dose i.p. TMZ (Figure 1A - B). The efficacy of MBZ as compared to TMZ was further 
demonstrated by a significant reduction in tumor volume as pictured in Figure 1C. No obvious 
toxicity was observed with MBZ treatment (Figure 1D).  
 
Consistent with our previous in vitro studies, MBZ induced Bcl2 phosphorylation in vivo in 
response to both doses tested (Figure 2). Additionally, decreased levels of XIAP and enhanced 
cleavage of caspase 3 and 9 was also observed in mice receiving MBZ (Figure 2). In contrast, no 
effect on Bcl2 or XIAP was observed in tumors obtained from mice following treatment with TMZ 
or DMSO (control).  
 
Mebendazole treatment causes XIAP downregulation 
Given XIAP’s critical role in the regulation of apoptosis, we investigated its function in MBZ 
mediated apoptosis. As shown in Figure 3A, treatment of M-14 and A-375 melanoma cells with 
0.5 μM MBZ results in a time dependent decrease in XIAP protein levels first evident at 24 hours 
following treatment. The decrease in XIAP levels in response to MBZ exposure inversely 
correlates with an increase in cleaved PARP (Figure 3A), a well-characterized marker of 
apoptosis. In addition to enhanced cleavage of PARP, we also observed enhanced cleavage of 
caspase 9 consistent with activation of the mitochondrial mediated apoptotic pathway (Figure 
3A).  
 
Upon conditions promoting apoptosis SMAC/DIABLO is capable of negatively regulating XIAP 
through selective binding to XIAP itself, thereby blocking inhibition of caspases by XIAP [23,24]. 
We therefore hypothesized that promotion of melanoma apoptosis by MBZ might be achieved 
through alterations of XIAP’s ability to interact with SMAC/DIABLO. To test this hypothesis, we 
immunoprecipitated XIAP from non-treated and MBZ-treated M-14 melanoma cell lines, and 
immunoblotted for SMAC/DIABLO. As shown in Figure 3B, a time dependent increase in 
SMAC/DIABLO association with XIAP is noted in MBZ treated cells as compared to untreated 
cells. This increase is initially detected 9 hours after treatment. Similar results were obtained 
when the opposite immunoprecipitation reaction was performed (i.e. SMAC/DIABLO 
immunoprecipitation, XIAP immunoblot). Altogether, these data suggest that MBZ treatment 
results in enhanced interaction of XIAP with SMAC/DIABLO, thereby alleviating XIAP’s inhibition 
on apoptosis.  
 
Mebendazole-mediated XIAP degradation does not occur in MBZ-resistant cells 
Given that XIAP has been linked to melanoma chemoresistance through its anti-apoptotic 
function, we wanted to determine whether XIAP expression could serve as a molecular marker for 
MBZ sensitivity in melanoma cell lines. To this end, we assessed XIAP levels in MBZ sensitive 
and resistant cell lines before and 24 hours following treatment with 1 μM MBZ. Interestingly, 
basal levels of XIAP in our panel of melanoma cell lines did not appear to be predictive of cellular 
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response to MBZ (Figure 4B). However, cells that were sensitive did show diminished levels of 
XIAP after treatment with MBZ whereas resistant cells (i.e. MBZ IC50 > 10 μM) did not (Figure 
4B). Reduced XIAP expression in response to MBZ treatment is partially reversible upon 
treatment with the proteasomal inhibitor MG132 (Figure 4A). These data suggest that the MBZ 
mediated decrease in XIAP levels results at least in part from its proteasomal degradation.  
 
Modulation of XIAP levels sensitizes MBZ-resistant cells to apoptosis 
Given that UACC1097 and D17 non-mutant BRAF melanoma cells are resistant to inhibition of 
growth by MBZ and do not display downregulation of XIAP upon treatment with MBZ (Figure 4B), 
we hypothesized that if XIAP was critical to MBZ induced apoptosis, MBZ-resistant cells should 
be rendered sensitive to MBZ if XIAP levels are reduced by siRNA. As shown in Figure 5, siRNA 
knockdown of XIAP results in a significant reduction in the levels of XIAP, whereas control, 
scrambled siRNA has no effect in both UACC1097 and D17 melanoma cells. Reduction of XIAP 
protein levels in UACC1097 and D17 melanoma cells rendered them more sensitive to the 
growth-inhibitory effects of MBZ compared with cells treated with a scrambled siRNA (Figure 5). 
These data are consistent with the notion that XIAP is a critical mediator of MBZ-induced 
apoptosis in melanoma cells. 
 
We originally identified MBZ as a potent inducer of BCL2 phosphorylation and apoptosis in 
melanoma cell lines [17]. MBZ is a drug with known microtubule disrupting properties that has 
been used safely as an antihelminthic agent in the treatment of parasitic infections for over 50 
years [7]. We found that phosphorylation of BCL2 in response to MBZ causes a decreased 
association with BAX, a condition that favors apoptosis [17]. BAX oligomerization promotes 
permeabilization of the outer mitochondrial membrane and subsequent release of apoptogenic 
proteins such as cytochrome C and SMAC/DIABLO [25].  
 
Our data suggest that MBZ has the potential to be repositioned as an anti-melanoma agent. At 
concentrations achievable with oral administration, MBZ is able to effectively inhibit proliferation 
of melanoma xenografts in vivo (Figure 2) [17]. This growth inhibition may be attributable to 
MBZ’s ability to target cellular anti-apoptotic machinery and thereby promote apoptosis (Figure 2, 
3). Of particular interest is the fact that mebendazole displays important pharmacokinetic 
properties (such as enhanced oral bioavailability and maximal plasma concentrations after oral 
administration that greatly exceed those necessary to induce apoptosis in melanoma cells) that 
make it an ideal candidate for further study in a clinical setting [26]. Additionally, several 
published studies demonstrate mebendazole’s ability to inhibit cellular proliferation in certain 
other cancer cells including lung, hepatocellular and adrenocortical carcinoma [27,28,29].  
 
Shi et al [30] recently found that downregulation of XIAP was a predictor of cellular response to 
microtubule disrupting agents. In addition to rapid phosphorylation of Bcl2 and its enhanced 
dissociation from BAX [17], we have now shown that MBZ treatment of melanoma cells results in 
downregulation of XIAP as well as increased interaction of remaining XIAP with SMAC/DIABLO, 
which has been previously shown to relieve XIAP’s inhibitory effects on apoptosis (Figure 3) 
[23,24]. Phosphorylation of BCL2 is an early event, occurring at 3 to 6 hours post MBZ treatment 
[17]. Our data show enhanced interaction between XIAP and SMAC/DIABLO by 9 hours 
(although it is possible that this occurs at earlier time points not evaluated), followed by down-
regulation of XIAP at 24 hours (Figure 1). Our data would suggest that this sequence of events is 
responsible for MBZ’s ability to promote apoptosis in melanoma cells. Additionally, in light of 
recent studies suggesting that renal cell cancer can be rendered sensitive to apoptosis through 
multiple targeting of XIAP and BCL2, a single agent like MBZ that impacts both proteins might 
prove valuable in overcoming apoptotic resistance to therapy in melanoma [31]. 
 
Previous studies have suggested that other microtubule binding agents like paclitaxel cause a 
diminution of XIAP levels through proteasomal degradation [32]. Additionally, recent data suggest 
that XIAP can function as an E3 ubiquitin ligase [33]. Furthermore, XIAP can regulate itself 
through auto-ubiquitination [34]. Several studies have also shown that XIAP agonists like 
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SMAC/DIABLO can trigger the degradation of XIAP [35]. Our data using the proteasomal inhibitor 
MG132 suggests that the reduction in XIAP protein levels observed upon treatment with MBZ is 
likely mediated by proteasomal degradation (Figure 3).  
 
We demonstrate that XIAP levels in response to treatment with MBZ correlate with sensitivity of 
melanoma cell lines to the anti-proliferative effects of MBZ (Figure 4). Interestingly, basal XIAP 
levels do not provide the same predictive value. This finding is also consistent with the report by 
Shi and coworkers who showed that sensitivity to paclitaxel and nocodazole does not correlate 
with pre-treatment levels of XIAP. Moreover, in keeping with the results reported here for MBZ, 
they found that sensitivity to microtubule targeting agents correlates with a loss of XIAP during 
the drug response [30].  
 
As key components of the cytoskeleton, microtubules are essential for cell structure, intracellular 
transport, mitosis and cell division [36]. Through disruption of the mitotic spindle, classical 
microtubule-targeted drugs such as paclitaxel and Vinca alkaloids exert their inhibitory effect on 
cancer cell proliferation through inhibition of tubulin degradation and polymerization, respectively. 
This anti-tubulin mechanism results in arrest of the cell-cycle at the metaphase-anaphase 
transition and induction of apoptosis [37,38]. However, melanoma fails to respond sufficiently to 
“classical” microtubule targeted drugs like paclitaxel and vinblastine [39]. Like the Vinca alkaloids, 
MBZ inhibits tubulin polymerization. However, it should be noted that MBZ possesses different 
tubulin binding properties than the classical anti-cancer drugs. MBZ binds to the colchicine 
binding site [40], whereas paclitaxel and vinblastine bind to the paclitaxel and vinblastine binding 
sites, respectively [36]. Therefore, it is reasonable to suggest that MBZ has the potential to be an 
effective anti-melanoma agent despite the disappointing results with other microtubule disrupting 
agents.  
 
In vivo, MBZ inhibits melanoma xenograft growth (Figure 1). Tumors of mice treated with MBZ 
exhibit activation of the apoptotic pathway as evidenced by caspase 3 and 9 cleavage (Figure 2). 
However, it should be noted that we did not observe regression in our in vivo model of human 
melanoma. While we showed that MBZ induces cell death in vitro and in vivo causes marked 
tumor growth inhibition, the question as to why we did not see tumor regression in the M14 
melanoma xenografts still remains. It is possible that in the presence of MBZ, equilibrium exists 
between cellular proliferation and cellular death in these xenografts. 
 
Previous in vivo studies have clearly demonstrated that MBZ is an effective anti-tumor agent in 
the treatment of lung and adrenocortical carcinomas at dosing concentrations of 1 and 2 mg 
[41,42]. Our decision to use similar MBZ doses in our study were based upon the efficacy of the 
aforementioned studies as well as our in vitro data demonstrating that MBZ potently inhibits 
melanoma cell growth and induces apoptosis at 0.5 µM in M-14 melanoma cells [17]. This 
concentration can be achieved in humans by giving 50 mg/kg orally per day as done in the 
treatment of cystic and alveolar echinococcosis and is equivalent to the 1 mg MBZ dose used in 
our xenograft studies [43]. Our data reveled that both 1 and 2 mg MBZ effectively inhibited 
melanoma xenograft growth, resulted in BCL2 phosphorylation and decreased XIAP expression, 
and was well tolerated (Figure 1 and 2). Because the effect of 1 mg MBZ appears to be strikingly 
similar to 2 mg MBZ and 1 mg MBZ dosing is clinically achievable using the dosing regimen 
established for the treatment of echinococcosis, we would conclude that this dose would be ideal 
for future clinical studies. 
 
Our data have clinical implications for the treatment of melanoma. Our in vivo data suggest that 
MBZ inhibits melanoma growth in an efficacious manner similar to TMZ (the current standard of 
care for non mutated BRAF melanoma) and is well tolerated (Figure 2). These studies lay the 
groundwork for further evaluation in a clinical trial of advanced melanoma.  
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Figure Legends:  
 
Figure 1. Mebendazole inhibits melanoma xenograft growth as effectively as TMZ. M-14 
melanoma cells were implanted into athymic nude mice to allow for xenograft formation. Mice 
were treated with 100mg/kg TMZ administered by i.p. injection daily for 5 days, 1 mg or 2 mg 
MBZ delivered by gavage every other day, or DMSO administered by i.p. injection daily for 5 days 
(control). Tumor volume was measured twice weekly during the 5 weeks of treatment. (A) 
Average tumor volume or (B) scatter plot of actual tumor volumes with best fit trend line for each 
treatment group is plotted as follows DMSO (■), TMZ (◊), 2 mg MBZ (×), 1 mg MBZ (□).  (C) 
Photograph of final tumor size after the course of treatment. Two representative tumors from 
each treatment group displayed. (D) Mean animal weight over the course of treatment for the 
following groups: DMSO (■), TMZ (◊), 2 mg MBZ (×), 1 mg MBZ (□). Error bars represent SEM. 
 
 
Figure 2. Tumors from mice treated with mebendazole reveal phosphorylation of BCL2 and 
reduction in XIAP levels. Mouse tumor extracted following treatment regimen were 
homogenized and immunoblotted for BCL2, XIAP, cleaved caspase 9 (CC9), cleaved caspase 3 
(C-C3) and actin (loading control). Expected protein sizes are as follows: Bcl2 = 26 KDa, XIAP = 
53 KDa, CC9 = 37 KDa, CC3 = 17 KDa and actin = 42 KDa. 
 
 
Figure 3. Mebendazole induced apoptotic response involves enhanced interaction of 
SMAC/DIABLO with XIAP. (A) M-14 and A-375 cells treated with 0.5 μM MBZ for 0, 18, 24 and 
48 hours. Extracted proteins were immunoblotted for cleaved caspase 9 (C-C9), cleaved PARP 
(C-PARP), XIAP and actin (loading control). (B) M-14 and A-375 cells were treated with 0.5 μM 
MBZ for 9, 18, 24 hours. Cellular lysate was immunoprecipitated using antibodies to SMAC or 
XIAP, then immunoblotted for SMAC/DIABLO or XIAP (as input control). Expected protein sizes 
are as follows: CC9 = 37 KDa, CPARP = 89 KDa, XIAP = 53 KDa, SMAC = 21KDa and actin = 42 
KDa. 
 
 
Figure 4. Reduction of XIAP expression upon treatment with mebendazole only occurs in 
sensitive melanoma cells. (A) M-14 cells treated with 0.5 μM MBZ for 24 hours in the presence 
or absence of 10 μM MG 132. (B) Indicated melanoma cell lines were treated with 0.5 μM MBZ 
for 24 hours. Cellular lysates were immunoblotted for XIAP and actin (loading control). MBZ IC50 
values for each cell line were determined through dosing experiment using the sulphorhodamine 
(SRB) assay. Expected protein sizes are as follows: XIAP = 53 KDa and actin = 42 KDa. 
 
 
Figure 5. XIAP siRNA renders resistant melanoma cells sensitive to mebendazole. D17 (A) 
and UACC1097 (B) melanoma cells were electroporated with vehicle alone (NT), XIAP siRNA, or 
control scrambled siRNA. Twenty-four hours after electroporation, extracted proteins were 
analyzed by immunoblotting using anti-XIAP and actin (loading control). D17 and UACC1097 
melanoma cells either electroporated with vehicle alone (□), XIAP siRNA (○), or control 
scrambled siRNA (Δ). Expected protein sizes are as follows: XIAP = 53 KDa and actin = 42 KDa. 
Cells were treated with indicated concentrations of mebendazole for 72 h. Cellular proliferation 
was determined using the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay. Points, 
mean of three independent experiments.   
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